KRAS G13D-mutant metastatic rectal cancer achieves 16.6 months disease control with TAS-102 plus bevacizumab

A 57-year-old man with KRAS G13D-mutant metastatic rectal cancer and fluoropyrimidine intolerance achieved approximately 16.6 months of disease control with trifluridine/tipiracil plus bevacizumab integrated with liver-directed treatments, substantially exceeding SUNLIGHT trial median PFS. (Anticancer Drugs)